


The listing of claims which follows replaces all previous versions.

1. (Original) A compound including resolved enantiomers, diastereomers, solvates and pharmaceutical acceptable salts thereof, said compound having the formula:



wherein if R₁ is hydrogen or -OH then R₂ is AX, and if R₂ is hydrogen or -OH then R₁ is AX, and A may be absent or A may be any alkyl or aryl group where X is hydrogen, a phosphate group, a phosphonic acid derivative group, an alcohol group, a carboxylic acid group, an ether group, an ester group, a nitrile group, a sulfone group, a sulfide group, an amino acid derivative group, an amine group, and amide group, an aldehyde group, or an aromatic group.

2. (Original) The compound of claim 1, wherein said alcohol group is represented by -R³OH, wherein R³ is a straight chained or branched alkyl group having 1 to 5 carbon atoms.

3. (Original) The compound of claim 1, wherein said carboxylic acid group comprises -R⁴COOH wherein R⁴ is at least one saturated or unsaturated alkyl group, an aryl group an ester group, an ether group or a combination thereof.

4. (Original) The compound of claim 3, wherein R⁴ is an ester group represented by -R⁵COO-, wherein R⁵ is bonded to the carboxylic acid group and has 0 to 5 carbon atoms.


5. (Original) The compound of claim 3, wherein R^4 is an ether group represented by R^6-O-R^7 wherein R^6 and R^7 are, independently, an alkyl or allyl group having 0 to 5 carbon atoms.
6. (Original) The compound of claim 1, wherein said aromatic group comprises $Ar-(R^8)_m$, wherein Ar represents a benzene ring, and m is 1 or 2.
7. (Original) The compound of claim 6, wherein R^8 is $-CH=CH_2$, or $-COOH$.
8. (Original) The compound of claim 1, wherein the ester group is represented by $-CR^9$, where R^9 is an ester of nicotinic acid, an ester of isonicotinic acid, or the ester group is represented by $-CO(C=O)R^{9a}$, where R^{9a} is $Ph(CY_3)_o$, where o is 1 or 2, and Y may be, independently, H, F, Cl, Br, or I, or where R^{9a} is a substituted heterocyclohexane compound.
9. (Original) The compound of claim 1, wherein the phosphonic acid derivative group is represented by $-CO-P(R^{10})(O)OH$, where R^{10} is an alkyl group having 0 to 5 carbon atoms.
10. The compound of claim 1, wherein the phosphate group is $-COP(O)(OR^{11})_2$, where R^{11} is an alkyl group having 0 to 5 carbon atoms, or a phenyl group.
11. (Original) The compound of claim 1, wherein the nitrile group is $R^{12}CN$, where R^{12} is an alkyl group having 0 to 5 carbon atoms.
12. (Original) The compound of claim 1, wherein the sulfone group is $-CS(=O)_2R^{13}$, wherein R^{13} is $-N(CH_3)_2$, $-OR^{14}$, or $-Ph-COOR^{14}$, where R^{14} is H, CH_3 , or $-CH(CH_3)_2$.
13. (Original) The compound of claim 1, wherein the sulfide group is $-CSR^{15}$, where R^{15} is pyridine or $-Ph-COOR^{16}$, where R^{16} is H or CH_3 .
14. (Original) The compound of claim 1, wherein the amino acid derivative group is $-COC(=O)CHR^{21}N(R^{17})_2$, where each R^{17} group is, independently, H or CH_3 and R^{21} is hydrogen or any other substituent.

15. (Original) The compound of claim 1, wherein the amine group is $\text{CN(R}^{18})_2$, where each R^{18} group is, independently, H, an alkyl group, or a phenyl group.

16. (Original) The compound of claim 1, wherein the ether group is C-O-CR^{19} , where R^{19} is a substituted pyridine.

17. (Original) The compound of claim 1, wherein the amide group is $\text{(C=O)N(R}^{20})_2$, or $\text{-CH}_2\text{(C=O)N(R}^{20})_2$ where each R^{20} is, independently, H or $\text{-CH}_2\text{CH}_2\text{N(CH}_3)_2$.

18. (Original) A compound including resolved enantiomers, diastereomers, solvates and pharmaceutical acceptable salts thereof, said compound having the formula:



where D forms a heterocyclic ring having 3 to 5 atoms.

19. (Original) The compound of claim 18, wherein the heterocyclic ring is a 3-membered ring and one of the atoms in the ring is oxygen.


20. (Original) The compound of claim 18, wherein the heterocyclic ring is a 5-membered ring and two of the atoms in the ring are oxygen.

21. (Original) The compound of claim 20, wherein the heterocyclic ring is substituted with an oxygen atom.

22. (Original) The compound of claim 21, wherein another atom in the 5-membered ring is a sulfur or a phosphorous atom.

23. (Original) The compound of claim 22, wherein the 5-membered ring is substituted with 1 or 2 oxygen atoms bonded to the sulfur atom.


24. (Original) A compound including resolved enantiomers, diastereomers, solvates and pharmaceutical acceptable salts thereof, said compound having the formula:




where E is H, O, NR, CH₂ or S wherein R may be hydrogen, alkyl, aryl or any other substituent.

25. (Original) The compound of claim 1 wherein if R₁ is H or -OH then


R₂ is




and if R₂ is OH or H then R₁ is





26. The compound of claim 1, wherein if R₁ is H or -OH then



and if




27. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




wherein R is hydrogen or a methyl group when n is 0 or 2.

28. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




wherein R may be $\text{CH}_2=\text{CH}$ or COOH .


29. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




30. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




31. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




32. (Original) The compound of claim 1, wherein if R₁ is H or -OH then




and if R₂ is -OH or H then R₁ is




33. (Original) The compound of claim 1, wherein if R₁ is H or -OH then



34. (Original) The compound of claim 1, wherein if R₁ is H or -OH then




35. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




36. (Currently amended) The compound of claim 1, wherein if R_1 is H then R_2 is -OH.

37. The compound of claim 1, wherein if R_1 is H or -OH then




38. (Original) The compound of claim 1, wherein if R_1 is H then R_2 is carboxylic acid.


39. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




40. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




41. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




42. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




43. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




44. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




45. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




46. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




47. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




48. (Original) The compound of claim 1, wherein if R_1 is H or -OH then



49. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




50. (Original) The compound of claim 1, wherein if R_1 is H or -OH then



51. (Original) The compound of claim 50 wherein R is a methyl or ethyl group.


52. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




53. (Original) The compound of claim 52 wherein R is a methyl group.

54. (Original) The compound of claim 52 wherein R is an iso-propyl group.


55. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




56. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




57. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




58. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




59. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




60. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




61. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




62. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




63. (Original) The compound of claim 1, wherein if R_1 is H or -OH then



64. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




65. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




66. (Original) The compound of claim 66 wherein each R' and R independently can be any amino acid of all possible stereochemistries and with any degree and choice of protecting group.


67. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




68. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




69. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




70. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




71. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




72. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




73. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




74. (Original) The compound of claim 1, wherein if R_1 is H or -OH then




75. (Original) The compound of claim 74, wherein R and R' are independently of each other hydrogen, alkyl, aryl, or allyl.

76. (Original) The compound of claim 19 wherein said heterocyclic ring is 


77. (Original) The compound of claim 21 wherein said heterocyclic ring




78. (Original) The compound of claim 22 wherein said heterocyclic ring




79. (Original) The compound of claim 21 wherein said heterocyclic ring




80. (Original) The compound of claim 22 wherein said heterocyclic ring




81. (Original) A compound including resolved enantiomers, diastereomers, solvates and pharmaceutical acceptable salts thereof, said compound having the formula:



82. (Original) A compound including resolved enantiomers, diastereomers, solvates and pharmaceutical acceptable salts thereof, said compound having the formula:



83. (Original) A compound including resolved enantiomers, diastereomers, solvates and pharmaceutical acceptable salts thereof, said compound having the formula:



84. (Currently amended) A method of treating cancer, which comprises administering to a patient suffering from said cancer [[a]] the compound of claim 1. ~~or combination of compounds of claims 1—83.~~

85. (Original) A method according to claim 84 wherein said cancer is selected from the group of cancers consisting of leukemia, non-small cell lung cancer, colon cancer, central nervous system cancer, melanoma cancer, ovarian cancer, renal cancer, prostate cancer, and breast cancer.

86. (Currently amended) A method for treating malaria comprising ~~adiministering~~ administering an effective amount of ~~[[a]]~~ the compound ~~or combination of compounds of claims 1-83.~~ of claim 1.